Pharmaceutical company AstraZeneca has disclosed that a Phase 3 trial of the diabetes drug Farxiga, also known as dapagliflozin, has shown that the drug did not help patients hospitalised with COVID-19 patients, news website CNN reported on Monday.
According to AstraZeneca, the DARE-19 trial did not show statistical significance in preventing organ dysfunction and death in hospitalised coronavirus patients who had other risk factors for severe COVID-19, which included hypertension, type 2 diabetes, cardiovascular disease and heart failure or chronic kidney disease.
This trial looked at a sodium-glucose co-transporter-2 inhibitor, or SGLT2, in hospitalised COVID-19 patients who have risk factors for developing serious complications. The SGLT2 inhibitors are described by the US Food and Drink Administration (FDA) as "a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes."
Dr Mikhail Kosiborod, a cardiologist at Saint Luke's Mid America Heart Institute and principal investigator of DARE-19, commented "DARE-19 provided important data on the potential benefits and risks of using SGLT2 inhibitors to treat hospitalized patients with Covid-19." He added: "While the trial did not achieve statistical significance, the findings are very interesting and valuable, and will inform future clinical science."
AstraZeneca stated that the full DARE-19 trial results will be presented at the American College of Cardiology Scientific Sessions in May 2021.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT